Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis

American Journal of Transplantation

Volumn 15, Issue 7, 2015, Pages 1817-1826

  Cortesi, P A ^a   Mantovani, L G ^b   Ciaccio, A ^a   Rota, M ^a   Mazzarelli, C ^c   Cesana, G ^a   Strazzabosco, M ^a,d   Belli, L S ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Economics; liver disease; liver transplantation: auxiliary; liver transplantation: living donor; liver transplantation: split

Indexed keywords

RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HIDDEN MARKOV MODEL; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; MIDDLE AGED; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; ADVERSE EFFECTS; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FOLLOW UP; HEPACIVIRUS; LIVER TRANSPLANTATION; MALE; PATHOGENICITY; POSTOPERATIVE COMPLICATION;

AGED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE;

EID: 84931444847     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13320     Document Type: Article

References (27)

1. Adam R, Karam V, Delvart V, et al., Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-688.
2. Italian National Transplant Center-Sistema Informativo Trapianto. [cited 2014 January 15]. Available from: https://trapianti.sanita.it/statistiche/home.asp.
3. Angelico M, Cillo U, Fagiuoli S, et al., Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155-164.
4. Crespo G, Mariño Z, Navasa M, Forns X,. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373-1383.
5. Prieto M, Berenguer M, Rayõn JM, et al., High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250-256.
6. Berenguer M, Prieto M, Rayõn JM, et al., Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858.
7. Roche B, Samuel D,. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012; 32: 120-128.
8. Curry MP, Forns X, Chung RT, et al., Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study. Gastroenterology 2015; 148: 100-107.
9. Afdhal N, Everson G, Calleja JL, et al., Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: Early virologic response and safety. J Hepatol 2014; 60: S28.
10. Gane EJ, Agarwal K,. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "A flood of opportunity." Am J Transplant 2014; 14: 994-1002.
11. Briggs A, Sculpher M, Claxton K,. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.
12. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M, On Behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force. Conceptualizing a model: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Value Health 2012; 15: 804-811.
13. Siebert U, Alagoz O, Bayoumi AM, et al., On Behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Health 2012; 15: 812-820.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
15. Cadahía V, González-Diéguez ML, Alonso P, et al., Exclusions and deaths on the liver transplant waiting list. Transplant Proc 2010; 42: 622-624.
16. Alazawi W, Cunningham M, Dearden J, Foster GR,. Systematic review: Outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344-355.
17. Cortesi PA, Scalone L, Ciampichini R, et al., Health related quality of life in the major liver conditions. Hepatology 2013; 58: 1210A.
18. Ciampichini R, Fagiuoli S, Scalone L, et al., Societal burden in Hepatits C patients: The COME study results. Value Health 2012; 15: A138.
19. Conferenza delle regioni e delle province autonome 13/41/cr05a/c7-Accordo interregionale per la compensazione della mobilità sanitaria. [cited 2014 May 4]. Available from: http://www.sanita.ilsole24ore.com/pdf 2010/Sanita2/-Oggetti-Correlati/Documenti/Regioni-e-Aziende/TUC-2012.pdf?uuid=5c5fbc90-a757-11e2-82ba-89cca4ad5083.
20. Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M,. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. Transpl Int 2013; 26: 527-534.
21. Cortesi PA, Ciaccio A, Rota M, et al., Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options. J Viral Hepat 2015; 22: 175-183.
22. Siebert U, Sroczynski G, Aidelsburger P, et al., Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: A decision analysis based on German guidelines. Pharmacoeconomics 2009; 27: 341-354.
23. Gazzetta Ufficiale Della Repubblica Italiana. [cited 2014 December 17]. Available from: http://www.gazzettaufficiale.it/atto/serie-generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta= 2014-12-05&atto.codiceRedazionale=14A09382&elenco30giorni=false.
24. Italian Medicines Agency (AIFA). [cited 2014 May 4]. Available at: http://www.agenziafarmaco.gov.it.
25. Hagan LM, Sulkowski MS, Schinazi RF,. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014; 60: 37-45.
26. Key challenges in HCV management in the transplant setting. [cited 2014 October 20]. Available from: http://www.clinicaloptions.com/Hepatitis/Treatment%20Updates/HCV%20Transplant/CCO%20Slidesets/Key-Challenges-%20for-Transplant.aspx.
27. U.S. Department of Health & Human Services. Organ procurement and transplantation network. OPTN/SRTR 2012 Annual Data Report: Liver. [cited 2014 October 20]. Available from: http://optn.transplant.hrsa.gov/converge/data/annualReport.asp.